Analysts forecast that Infinity Pharmaceuticals Inc. (NASDAQ:INFI) will post $850,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Infinity Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.50 million and the lowest estimate coming in at $200,000.00. Infinity Pharmaceuticals posted sales of $22.00 million during the same quarter last year, which suggests a negative year-over-year growth rate of 96.1%. The company is scheduled to announce its next earnings results on Monday, November 4th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year sales of $3.93 million for the current financial year, with estimates ranging from $2.00 million to $7.00 million. For the next year, analysts expect that the firm will post sales of $800,000.00. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.03). The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $2.60 million. Infinity Pharmaceuticals had a negative return on equity of 42.16% and a negative net margin of 77.80%.
A number of hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its holdings in Infinity Pharmaceuticals by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,002,006 shares of the biotechnology company’s stock worth $1,804,000 after buying an additional 110,806 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Infinity Pharmaceuticals by 10.9% in the second quarter. Acadian Asset Management LLC now owns 601,517 shares of the biotechnology company’s stock valued at $1,083,000 after purchasing an additional 58,998 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Infinity Pharmaceuticals by 5.0% in the second quarter. Jacobs Levy Equity Management Inc. now owns 201,438 shares of the biotechnology company’s stock valued at $363,000 after purchasing an additional 9,511 shares in the last quarter. Evercore Wealth Management LLC lifted its holdings in shares of Infinity Pharmaceuticals by 20.7% in the second quarter. Evercore Wealth Management LLC now owns 143,138 shares of the biotechnology company’s stock valued at $258,000 after purchasing an additional 24,553 shares in the last quarter. Finally, Athanor Capital LP purchased a new stake in shares of Infinity Pharmaceuticals in the second quarter valued at about $177,000. 53.84% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:INFI traded down $0.04 during midday trading on Friday, hitting $1.12. 34,369 shares of the company were exchanged, compared to its average volume of 143,368. The company has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $1.45. Infinity Pharmaceuticals has a fifty-two week low of $0.96 and a fifty-two week high of $2.68. The company has a current ratio of 7.93, a quick ratio of 7.93 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $66.45 million, a PE ratio of -5.60 and a beta of 1.82.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Further Reading: What are popular range trading strategies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.